- Home
- GALT vs ARCT Comparison
GALT vs ARCT Comparison
Compare GALT & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | ARCT |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 192.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | ARCT |
|---|---|---|
| Price | $2.84 | $7.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $8.50 | ★ $38.44 |
| AVG Volume (30 Days) | 322.0K | ★ 506.2K |
| Earning Date | 11-14-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $97,601,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.12 | $5.85 |
| 52 Week High | $7.13 | $24.17 |
Technical Indicators
Market Signals| Indicator | GALT | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 59.71 |
| Support Level | $2.61 | $7.00 |
| Resistance Level | $3.30 | $7.63 |
| Average True Range (ATR) | 0.23 | 0.42 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 21.05 | 87.37 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.